Friday, March 29, 2024
-Advertisement-
Reimagining Public Sector Analytics
Reimagining Public Sector Analytics
HomeNewsANGLE establishes co-marketing agreement with QIAGEN

ANGLE establishes co-marketing agreement with QIAGEN

Follow Tech Observer on Google News
Google News

, a liquid biopsy company, said it has established a co-marketing agreement with , a provider of molecular testing solutions with more than 500,000 customers in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharma and biotech companies) and Academia (life sciences research).

The partnership will seek to leverage the advantages of combining ANGLE's leading Parsortix system for harvesting circulating tumor cells (CTCs) with QIAGEN's liquid biopsy solution portfolio which consists of dedicated NGS (next generation sequencing), PCR (polymerase chain reaction), single cell analysis products and bioinformatics capabilities. The initial focus will be on prostate and breast cancer research applications.

The agreement entails both companies offering the other's products to its customer base and follows an intensive evaluation of Parsortix by QIAGEN identifying the advantages of the system.

“ANGLE's Parsortix system is a unique, epitope-independent CTC solution offering easy, automated processing of whole blood to harvest all types of CTCs, including the clinically relevant mesenchymal CTCs, for analysis. It complements very well with our AdnaTest CTC portfolio, now allowing for both phenotypic and molecular characterization of CTCs. The modular combination abilities of this system with QIAGEN's liquid biopsy-based Sample to Insight offering, including AdnaTest, our targeted RNAseq and single cell solutions, along with our bioinformatics offering, will allow scientists and clinical researchers to significantly advance their research,” said Michael Kazinski, QIAGEN's Senior Director Molecular Preanalytic Technologies.

“We are delighted that Parsortix has been selected by QIAGEN as their label-free CTC harvesting technology. We believe the ability to offer customers a combination of Parsortix with validated and reliable downstream analysis technologies from a world leader such as QIAGEN facilitates key aspects of the sales cycle and we look forward to working closely together. Partnering is a core part of ANGLE's strategy to secure widespread adoption of Parsortix right across the market leveraging the customer base and distribution channels of established players,” said ANGLE Founder and Chief Executive, Andrew Newland.

(This story has not been edited by Tech Observer staff and is auto-generated from a syndicated feed.)

Get the day's headlines from Tech Observer straight in your inbox

By subscribing you agree to our Privacy Policy, T&C and consent to receive newsletters and other important communications.
Tech Observer Desk
Tech Observer Desk
Tech Observer Desk at TechObserver.in is a team of technology reporters led by a senior editor who brings latest updates and developments from the world of technology.
- Advertisement -
Reimagining Public Sector Analytics
Reimagining Public Sector Analytics
- Advertisement -Veeam
- Advertisement -Reimagining Public Sector Analytics
- Advertisement -ESDS SAP Hana

Subscribe to our Newsletter

83000+ Industry Leaders read it everyday

By subscribing you agree to our Privacy Policy, T&C and consent to receive newsletters and other important communications.
- Advertisement -

How AI power struggle opens up new frontier in global geopolitics

The far-reaching influence AI has on information processing, national security, military operations, the economy, and strategic decision-making is set to reshape the geopolitical landscape and redefine the power dynamics between nations.

RELATED ARTICLES